Prospect Biosystems’ patent-pending Edge™ Technology is breakthrough non-denaturing, density based fractionation, separation technology, and biomarker evaluation and validation platform. The ability to rapidly and efficiently identify biomarkers and quickly analyze complex biological components of tissue and cell samples will accelerate biomarker discovery; facilitate and advance pharmaceutical product development; accelerate many life sciences research; reduce false positive margins and improve outcomes for cancer and other surgical procedures; and improve efficiency and reduce costs of many healthcare delivery problems.

Edge Technology maintains biological context and tracks biological changes (click here for a schematic demonstration)

Edge platform includes:

• Edge and Centricollation™
  
  
• EDGE*TEST™
  
  
• Follow the Biology

Prospect ... "Exploration for useful or valuable things

and substances"